Switch to:
Also traded in: Denmark, Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.39
NVZMY's Cash to Debt is ranked lower than
90% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NVZMY: 0.39 )
Ranked among companies with meaningful Cash to Debt only.
NVZMY' s Cash to Debt Range Over the Past 10 Years
Min: 0.15  Med: 0.88 Max: No Debt
Current: 0.39
Equity to Asset 0.62
NVZMY's Equity to Asset is ranked lower than
58% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NVZMY: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
NVZMY' s Equity to Asset Range Over the Past 10 Years
Min: 0.53  Med: 0.62 Max: 0.67
Current: 0.62
0.53
0.67
Interest Coverage 226.33
NVZMY's Interest Coverage is ranked lower than
71% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVZMY: 226.33 )
Ranked among companies with meaningful Interest Coverage only.
NVZMY' s Interest Coverage Range Over the Past 10 Years
Min: 4.32  Med: 17.32 Max: 228.59
Current: 226.33
4.32
228.59
F-Score: 8
Z-Score: 18.17
WACC vs ROIC
8.01%
26.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 27.73
NVZMY's Operating margin (%) is ranked higher than
91% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NVZMY: 27.73 )
Ranked among companies with meaningful Operating margin (%) only.
NVZMY' s Operating margin (%) Range Over the Past 10 Years
Min: 18.46  Med: 22.02 Max: 27.74
Current: 27.73
18.46
27.74
Net-margin (%) 20.90
NVZMY's Net-margin (%) is ranked higher than
89% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NVZMY: 20.90 )
Ranked among companies with meaningful Net-margin (%) only.
NVZMY' s Net-margin (%) Range Over the Past 10 Years
Min: 13.04  Med: 16.99 Max: 20.9
Current: 20.9
13.04
20.9
ROE (%) 26.43
NVZMY's ROE (%) is ranked higher than
95% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NVZMY: 26.43 )
Ranked among companies with meaningful ROE (%) only.
NVZMY' s ROE (%) Range Over the Past 10 Years
Min: 21.35  Med: 23.41 Max: 29.87
Current: 26.43
21.35
29.87
ROA (%) 16.40
NVZMY's ROA (%) is ranked higher than
95% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NVZMY: 16.40 )
Ranked among companies with meaningful ROA (%) only.
NVZMY' s ROA (%) Range Over the Past 10 Years
Min: 11.3  Med: 13.79 Max: 16.4
Current: 16.4
11.3
16.4
ROC (Joel Greenblatt) (%) 36.83
NVZMY's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NVZMY: 36.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVZMY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 29.65  Med: 34.45 Max: 37.82
Current: 36.83
29.65
37.82
Revenue Growth (3Y)(%) 8.60
NVZMY's Revenue Growth (3Y)(%) is ranked higher than
58% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NVZMY: 8.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVZMY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 6.4  Med: 8.6 Max: 11.4
Current: 8.6
6.4
11.4
EBITDA Growth (3Y)(%) 21.40
NVZMY's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NVZMY: 21.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVZMY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1  Med: 9.4 Max: 23.6
Current: 21.4
-1
23.6
EPS Growth (3Y)(%) 12.90
NVZMY's EPS Growth (3Y)(%) is ranked higher than
70% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NVZMY: 12.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVZMY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 9.6  Med: 12.9 Max: 19.2
Current: 12.9
9.6
19.2
» NVZMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NVZMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ALXN, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, OTCPK:CSLLY, NAS:BMRN, OTCPK:UCBJF, NAS:MDVN, NAS:REGN, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:ALNY, NAS:TSRO, NAS:UTHR, NAS:GRFS, NAS:ANAC, NAS:IONS, NAS:ICPT » details
Traded in other countries:NZYM B.Denmark, NZM2.Germany, NZYMB.Switzerland, 0Q4U.UK,
Novozymes A/S is a biotech company. The Company is engaged in research, development, production and selling enzymes and microorganisms.

Novozymes A/S is a biotech company. It is engaged in research, development, production and selling enzymes and microorganisms. The Company offers biological solutions that help customer create more with less and improve performance. It sells products for applications as diverse as detergents, biofuels, agriculture, food and beverages, biopharmaceuticals, wastewater, textiles and pulp & paper. It operates in four geographical regions; Europe/MEA (including Denmark), North America, Asia Pacific and Latin America. Its products include LpHera, RONOZYME MultiGrain, Medley, DeniLite Cold, Leviti, Amplify, and Eversa.

Ratios

vs
industry
vs
history
P/E(ttm) 30.55
NVZMY's P/E(ttm) is ranked lower than
54% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. NVZMY: 30.55 )
Ranked among companies with meaningful P/E(ttm) only.
NVZMY' s P/E(ttm) Range Over the Past 10 Years
Min: 12.31  Med: 29.84 Max: 42.05
Current: 30.55
12.31
42.05
Forward P/E 26.53
NVZMY's Forward P/E is ranked lower than
69% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. NVZMY: 26.53 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.55
NVZMY's PE(NRI) is ranked lower than
54% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVZMY: 30.55 )
Ranked among companies with meaningful PE(NRI) only.
NVZMY' s PE(NRI) Range Over the Past 10 Years
Min: 12.3  Med: 29.84 Max: 42.05
Current: 30.55
12.3
42.05
Price/Owner Earnings (ttm) 45.54
NVZMY's Price/Owner Earnings (ttm) is ranked lower than
58% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. NVZMY: 45.54 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVZMY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 17.62  Med: 40.24 Max: 595.97
Current: 45.54
17.62
595.97
P/B 16.17
NVZMY's P/B is ranked lower than
90% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. NVZMY: 16.17 )
Ranked among companies with meaningful P/B only.
NVZMY' s P/B Range Over the Past 10 Years
Min: 5.11  Med: 6.58 Max: 18.37
Current: 16.17
5.11
18.37
P/S 6.46
NVZMY's P/S is ranked higher than
67% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. NVZMY: 6.46 )
Ranked among companies with meaningful P/S only.
NVZMY' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 5.12 Max: 12.83
Current: 6.46
2.25
12.83
PFCF 43.94
NVZMY's PFCF is ranked lower than
68% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. NVZMY: 43.94 )
Ranked among companies with meaningful PFCF only.
NVZMY' s PFCF Range Over the Past 10 Years
Min: 16.39  Med: 41.85 Max: 169.47
Current: 43.94
16.39
169.47
POCF 27.55
NVZMY's POCF is ranked lower than
57% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. NVZMY: 27.55 )
Ranked among companies with meaningful POCF only.
NVZMY' s POCF Range Over the Past 10 Years
Min: 14.51  Med: 22.62 Max: 93.72
Current: 27.55
14.51
93.72
EV-to-EBIT 48.94
NVZMY's EV-to-EBIT is ranked lower than
75% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. NVZMY: 48.94 )
Ranked among companies with meaningful EV-to-EBIT only.
NVZMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.5  Med: 23.3 Max: 67.7
Current: 48.94
9.5
67.7
EV-to-EBITDA 48.94
NVZMY's EV-to-EBITDA is ranked lower than
78% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. NVZMY: 48.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVZMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.5  Med: 23.1 Max: 67.7
Current: 48.94
9.5
67.7
PEG 1.66
NVZMY's PEG is ranked higher than
60% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.18 vs. NVZMY: 1.66 )
Ranked among companies with meaningful PEG only.
NVZMY' s PEG Range Over the Past 10 Years
Min: 0.82  Med: 2.59 Max: 5.03
Current: 1.66
0.82
5.03
Current Ratio 1.80
NVZMY's Current Ratio is ranked lower than
79% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. NVZMY: 1.80 )
Ranked among companies with meaningful Current Ratio only.
NVZMY' s Current Ratio Range Over the Past 10 Years
Min: 1.54  Med: 1.8 Max: 2.37
Current: 1.8
1.54
2.37
Quick Ratio 1.12
NVZMY's Quick Ratio is ranked lower than
84% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. NVZMY: 1.12 )
Ranked among companies with meaningful Quick Ratio only.
NVZMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.98  Med: 1.16 Max: 1.67
Current: 1.12
0.98
1.67
Days Inventory 142.91
NVZMY's Days Inventory is ranked lower than
53% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. NVZMY: 142.91 )
Ranked among companies with meaningful Days Inventory only.
NVZMY' s Days Inventory Range Over the Past 10 Years
Min: 134.08  Med: 138.63 Max: 150.56
Current: 142.91
134.08
150.56
Days Sales Outstanding 64.37
NVZMY's Days Sales Outstanding is ranked lower than
51% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. NVZMY: 64.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVZMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.43  Med: 66.23 Max: 69.67
Current: 64.37
63.43
69.67
Days Payable 65.86
NVZMY's Days Payable is ranked higher than
56% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. NVZMY: 65.86 )
Ranked among companies with meaningful Days Payable only.
NVZMY' s Days Payable Range Over the Past 10 Years
Min: 44.15  Med: 62.7 Max: 79.21
Current: 65.86
44.15
79.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.15
NVZMY's Dividend Yield is ranked higher than
50% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. NVZMY: 1.15 )
Ranked among companies with meaningful Dividend Yield only.
NVZMY' s Dividend Yield Range Over the Past 10 Years
Min: 0.65  Med: 0.97 Max: 1.4
Current: 1.15
0.65
1.4
Dividend Payout 0.36
NVZMY's Dividend Payout is ranked lower than
54% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. NVZMY: 0.36 )
Ranked among companies with meaningful Dividend Payout only.
NVZMY' s Dividend Payout Range Over the Past 10 Years
Min: 0.36  Med: 1.17 Max: 1.44
Current: 0.36
0.36
1.44
Dividend Growth (3y) 16.40
NVZMY's Dividend Growth (3y) is ranked higher than
73% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. NVZMY: 16.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVZMY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 29.5
Current: 16.4
0
29.5
Forward Dividend Yield 1.18
NVZMY's Forward Dividend Yield is ranked higher than
52% of the 195 Companies
in the Global Biotechnology industry.

( Industry Median: 1.18 vs. NVZMY: 1.18 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.34
NVZMY's Yield on cost (5-Year) is ranked higher than
75% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 1.44 vs. NVZMY: 3.34 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVZMY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.84  Med: 2.74 Max: 3.96
Current: 3.34
1.84
3.96
3-Year Average Share Buyback Ratio 0.90
NVZMY's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. NVZMY: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVZMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.6  Med: 0.7 Max: 6.4
Current: 0.9
-0.6
6.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.77
NVZMY's Price/Tangible Book is ranked lower than
89% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. NVZMY: 20.77 )
Ranked among companies with meaningful Price/Tangible Book only.
NVZMY' s Price/Tangible Book Range Over the Past 10 Years
Min: 7.06  Med: 8.81 Max: 23.16
Current: 20.77
7.06
23.16
Price/Projected FCF 2.70
NVZMY's Price/Projected FCF is ranked higher than
57% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. NVZMY: 2.70 )
Ranked among companies with meaningful Price/Projected FCF only.
NVZMY' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.44  Med: 3.16 Max: 4.07
Current: 2.7
2.44
4.07
Price/DCF (Earnings Based) 1.57
NVZMY's Price/DCF (Earnings Based) is ranked lower than
65% of the 20 Companies
in the Global Biotechnology industry.

( Industry Median: 1.06 vs. NVZMY: 1.57 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.23
NVZMY's Price/Median PS Value is ranked lower than
66% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. NVZMY: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
NVZMY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.44  Med: 1.02 Max: 2.34
Current: 1.23
0.44
2.34
Price/Peter Lynch Fair Value 4.35
NVZMY's Price/Peter Lynch Fair Value is ranked lower than
82% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. NVZMY: 4.35 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NVZMY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.51  Med: 2.18 Max: 4.85
Current: 4.35
0.51
4.85
Price/Graham Number 5.26
NVZMY's Price/Graham Number is ranked lower than
77% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.74 vs. NVZMY: 5.26 )
Ranked among companies with meaningful Price/Graham Number only.
NVZMY' s Price/Graham Number Range Over the Past 10 Years
Min: 2.01  Med: 3.42 Max: 5.87
Current: 5.26
2.01
5.87
Earnings Yield (Greenblatt) (%) 2.02
NVZMY's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. NVZMY: 2.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVZMY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 4.3 Max: 10.5
Current: 2.02
1.5
10.5
Forward Rate of Return (Yacktman) (%) 9.42
NVZMY's Forward Rate of Return (Yacktman) (%) is ranked lower than
59% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 14.98 vs. NVZMY: 9.42 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVZMY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2.7  Med: 14.7 Max: 39.8
Current: 9.42
2.7
39.8

More Statistics

Revenue (TTM) (Mil) $2,090
EPS (TTM) $ 1.43
Beta1.11
Short Percentage of Float0.00%
52-Week Range $37.98 - 49.55
Shares Outstanding (Mil)606.50

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2,175 2,303 2,402
EPS ($) 1.50 1.63 1.69
EPS w/o NRI ($) 1.50 1.63 1.69
EPS Growth Rate
(3Y to 5Y Estimate)
10.54%
Dividends Per Share ($) 0.58 0.64 0.74
» More Articles for NVZMY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
ETF’s with exposure to Novozymes A/S : September 30, 2016 Sep 30 2016
Coverage initiated on Novozymes by Berenberg Sep 27 2016
ETF’s with exposure to Novozymes A/S : August 29, 2016 Aug 29 2016
Novozymes A/S :NVZMY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
How Portfolio Shifts Are Affecting Fidelity’s Europe Fund Jul 27 2016
ETF’s with exposure to Novozymes A/S : June 30, 2016 Jun 30 2016
Novozymes A/S :NVZMY-US: Earnings Analysis: Q1, 2016 By the Numbers : June 3, 2016 Jun 03 2016
Consumer Staples Delivered Top-Notch Performance for VGEAX Apr 29 2016
Timely Energy Exposure Helped FHJUX in 1Q16 Apr 28 2016
ETF’s with exposure to Novozymes A/S : March 29, 2016 Mar 29 2016
Novozymes A/S :NVZMY-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 28 2016
An Above-Average Year for FHJUX Mar 21 2016
The Fidelity Advisor Europe Fund: An Above-Average Year Feb 22 2016
How the Fidelity Advisor Europe Fund Allocated Its Portfolio in 2015 Jan 25 2016
Novozymes A/S Earnings Analysis: Q4, 2015 By the Numbers Jan 21 2016
Novozymes A/S Earnings Analysis: Q4, 2015 By the Numbers Jan 21 2016
A Look at FHJUX’s Portfolio through November 2015 Dec 23 2015
The Fidelity Advisor Europe Fund Class A (FHJUX): Historical Overview Oct 28 2015
Novozymes A/S Earnings Q3, 2015 Oct 27 2015
Novozymes A/S – Value Analysis (US OTC:NVZMY) : October 23, 2015 Oct 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)